DBV Technologies (NASDAQ:DBVT) Shares Up 6.2% – Here’s Why

DBV Technologies S.A. (NASDAQ:DBVT) shot up 6.2% during trading on Monday . The stock traded as high as $14.77 and last traded at $14.8850. 45,287 shares were traded during trading, a decline of 85% from the average session volume of 304,978 shares. The stock had previously closed at $14.02.

Analyst Ratings Changes

Several equities analysts have recently weighed in on the stock. HC Wainwright reiterated a “buy” rating on shares of DBV Technologies in a research note on Tuesday, June 30th. Citizens Jmp upped their price target on shares of DBV Technologies from $47.00 to $55.00 and gave the company a “market outperform” rating in a research note on Tuesday, June 30th. Guggenheim reiterated a “buy” rating and issued a $51.00 price objective on shares of DBV Technologies in a research note on Monday, May 4th. Wall Street Zen cut shares of DBV Technologies from a “hold” rating to a “sell” rating in a report on Saturday, July 4th. Finally, Citigroup restated an “outperform” rating on shares of DBV Technologies in a research report on Friday, May 1st. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $48.50.

DBV Technologies Price Performance

The stock has a market capitalization of $930.00 million, a PE ratio of -4.21 and a beta of -0.93. The business’s fifty day moving average price is $15.21 and its 200-day moving average price is $18.70.

DBV Technologies (NASDAQ:DBVT) last issued its quarterly earnings data on Thursday, July 16th. The company reported ($0.60) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.48). The firm had revenue of $0.70 million for the quarter, compared to analysts’ expectations of $0.90 million. DBV Technologies had a negative net margin of 3,506.53% and a negative return on equity of 119.33%. On average, analysts expect that DBV Technologies S.A. will post -2.05 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of DBVT. Dorsey Wright & Associates purchased a new stake in shares of DBV Technologies in the first quarter worth $2,142,000. Diversify Wealth Management LLC purchased a new position in DBV Technologies during the first quarter worth about $1,293,000. Elmind Capital LP purchased a new position in DBV Technologies during the first quarter worth about $5,536,000. UBS Group AG increased its stake in DBV Technologies by 165,347.3% in the 4th quarter. UBS Group AG now owns 244,862 shares of the company’s stock worth $4,694,000 after acquiring an additional 244,714 shares during the last quarter. Finally, Perceptive Advisors LLC bought a new position in DBV Technologies in the 1st quarter worth about $20,146,000. 71.74% of the stock is owned by institutional investors.

DBV Technologies Company Profile

DBV Technologies SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.

The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents.